CY1110723T1 - Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc - Google Patents
Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhcInfo
- Publication number
- CY1110723T1 CY1110723T1 CY20101100714T CY101100714T CY1110723T1 CY 1110723 T1 CY1110723 T1 CY 1110723T1 CY 20101100714 T CY20101100714 T CY 20101100714T CY 101100714 T CY101100714 T CY 101100714T CY 1110723 T1 CY1110723 T1 CY 1110723T1
- Authority
- CY
- Cyprus
- Prior art keywords
- peptide
- relates
- mhc molecules
- peptides
- nos
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4238—Regulators of development
- A61K40/424—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/828—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Endocrinology (AREA)
Abstract
Η εφεύρεση αφορά ένα σχετιζόμενο με όγκους πεπτίδιο με μία αμινοξική αλληλουχία που επιλέχθηκε από την ομάδα αποτελούμενη από αλληλ. με τον αναγνωριστικό αριθμ. 1 έως αναγνωριστικό αριθμ. 79 από το συνημμένο πρωτόκολλο αλληλουχίας, όπου το πεπτίδιο παρουσιάζει την ικανότητα να δεσμεύει ένα μόριο του ανθρώπινου μείζονος συμπλέγματος ιστοσυμβατότητας (MHC) κλάσης I. Η εφεύρεση αφορά περαιτέρω την χρήση των πεπτιδίων για την παρασκευή ενός φαρμάκου και για την θεραπεία των καρκινικών νόσων. Επίσης περιγράφεται μία φαρμακευτική σύνθεση, η οποία παρουσιάζει τουλάχιστον ένα από τα πεπτίδια.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10225144A DE10225144A1 (de) | 2002-05-29 | 2002-05-29 | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| EP08014305A EP2014673B1 (de) | 2002-05-29 | 2003-03-27 | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1110723T1 true CY1110723T1 (el) | 2015-06-10 |
Family
ID=29557592
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081101297T CY1108507T1 (el) | 2002-05-29 | 2008-11-13 | Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc |
| CY20081101425T CY1108673T1 (el) | 2002-05-29 | 2008-12-09 | Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc |
| CY20081101508T CY1108680T1 (el) | 2002-05-29 | 2008-12-30 | Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc |
| CY20101100714T CY1110723T1 (el) | 2002-05-29 | 2010-07-30 | Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc |
| CY20101100991T CY1111174T1 (el) | 2002-05-29 | 2010-11-03 | Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081101297T CY1108507T1 (el) | 2002-05-29 | 2008-11-13 | Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc |
| CY20081101425T CY1108673T1 (el) | 2002-05-29 | 2008-12-09 | Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc |
| CY20081101508T CY1108680T1 (el) | 2002-05-29 | 2008-12-30 | Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100991T CY1111174T1 (el) | 2002-05-29 | 2010-11-03 | Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc |
Country Status (15)
| Country | Link |
|---|---|
| US (5) | US7396904B2 (el) |
| EP (5) | EP1507795B1 (el) |
| JP (5) | JP4472520B2 (el) |
| AT (5) | ATE416188T1 (el) |
| AU (2) | AU2003224001B2 (el) |
| CA (5) | CA2736921C (el) |
| CY (5) | CY1108507T1 (el) |
| DE (6) | DE10225144A1 (el) |
| DK (5) | DK2006294T3 (el) |
| ES (5) | ES2317379T3 (el) |
| HR (1) | HRP20041108B1 (el) |
| PL (5) | PL206306B1 (el) |
| PT (5) | PT2006294E (el) |
| SI (5) | SI2006294T1 (el) |
| WO (1) | WO2003102023A1 (el) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| US20050221350A1 (en) | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
| DE10225139A1 (de) * | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| US7670604B2 (en) | 2002-12-13 | 2010-03-02 | Aurelium Biopharma, Inc. | Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| DK2359841T3 (en) * | 2003-01-30 | 2015-02-02 | Survac Aps | Survivin-derived peptides and the use thereof |
| DE10313819A1 (de) * | 2003-03-24 | 2004-10-07 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| KR101176673B1 (ko) * | 2003-12-01 | 2012-08-23 | 가부시키가이샤 메이지 | 앤지오텐신 변환 효소 저해 팹티드 |
| JP2007515924A (ja) * | 2003-12-15 | 2007-06-21 | アウレリウム バイオファーマ インク． | ビメンチン指向性診断法、および、多剤耐性を示す腫瘍性疾患の治療法 |
| DE102004011503A1 (de) * | 2004-01-28 | 2005-09-15 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung und Quantifizierung von tumor-assoziierten Peptiden |
| DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| EP1642905B1 (en) * | 2004-10-02 | 2009-01-21 | Immatics Biotechnologies GmbH | Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes |
| IL172896A0 (en) * | 2005-12-29 | 2006-06-11 | Yeda Res & Dev | Cxcr4 inhibition |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| WO2009015842A2 (en) * | 2007-07-27 | 2009-02-05 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
| WO2009129498A2 (en) * | 2008-04-17 | 2009-10-22 | Immuneregen Biosciences, Inc. | Substance p and analogs thereof as a cancer immunogenic composition adjuvant |
| DK2119726T5 (en) | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
| CN101451975B (zh) * | 2008-12-29 | 2012-01-25 | 浙江大学 | 一种检测胃癌预后与分期血清蛋白质的方法 |
| US8075895B2 (en) * | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| US9555074B2 (en) | 2010-10-08 | 2017-01-31 | Regents Of The University Of Minnesota | Annexin II compositions |
| MY191939A (en) * | 2013-08-05 | 2022-07-19 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors, such as lung cancer, including nsclc |
| JPWO2015050259A1 (ja) * | 2013-10-03 | 2017-03-09 | 大日本住友製薬株式会社 | 腫瘍抗原ペプチド |
| AU2014348645B2 (en) | 2013-11-13 | 2019-01-24 | Regents Of The University Of Minnesota | Annexin II variant compositions and methods |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| ES2970246T3 (es) | 2015-03-27 | 2024-05-27 | Immatics Biotechnologies Gmbh | Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| IL308735A (en) | 2015-07-01 | 2024-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520558D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
| GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| SG10202111399YA (en) | 2015-12-22 | 2021-11-29 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| DE102016005550B4 (de) | 2016-05-09 | 2024-09-26 | Hans-Georg Rammensee | Adjuvans zur lnduzierung einer zellulären lmmunantwort |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102184377B1 (ko) | 2018-02-19 | 2020-11-30 | 고려대학교 산학협력단 | 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도 |
| WO2019160383A1 (ko) * | 2018-02-19 | 2019-08-22 | 고려대학교 산학협력단 | 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도 |
| BR102018010523A2 (pt) * | 2018-05-23 | 2020-04-28 | Univ Estadual Campinas Unicamp | peptídeo, composição farmacêutica compreendendo o mesmo e uso |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810781A (en) * | 1987-01-15 | 1989-03-07 | The George Washington University | Methods of preparing epitopes of tumor associated antigens |
| US5739009A (en) * | 1996-12-12 | 1998-04-14 | Incyte Pharmaceuticals, Inc. | Adipocyte-specific differentiation-related protein |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| DE19837015C2 (de) * | 1998-08-14 | 2003-03-20 | Vasopharm Biotech Gmbh | Isolierte und gereinigte humane lösliche Guanylylcyclase alpha1/beta1 (hsGCalpha1/beta1) |
| DE19936563A1 (de) | 1999-08-04 | 2001-02-08 | Boehringer Ingelheim Int | Tumorassoziiertes Antigen |
| US6809179B1 (en) | 1999-08-04 | 2004-10-26 | Boehringer Ingelheim International Gmbh | Tumor-associated antigen (R11) |
| AU2001233957A1 (en) * | 2000-02-24 | 2001-09-03 | Oxford Glycosciences (Uk) Limited | Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression |
| WO2002050103A2 (en) * | 2000-12-20 | 2002-06-27 | Glaxosmithkline Biologicals S.A. | Tumour-related antigens |
| US20030170719A1 (en) * | 2000-12-28 | 2003-09-11 | Akio Matsuda | NF-kappa B activating gene |
| CA2444691A1 (en) * | 2001-04-18 | 2002-10-31 | Protein Design Labs, Inc. | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| US6867283B2 (en) * | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| WO2002101075A2 (en) * | 2001-06-13 | 2002-12-19 | Millennium Pharmaceuticals, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer |
| AU2002346613A1 (en) * | 2001-12-03 | 2003-06-17 | Michael Bowen | Polynucleotides and polypeptides associated with the development of rheumatoid arthritis |
-
2002
- 2002-05-29 DE DE10225144A patent/DE10225144A1/de not_active Ceased
-
2003
- 2003-03-27 JP JP2004509714A patent/JP4472520B2/ja not_active Expired - Fee Related
- 2003-03-27 PT PT08014304T patent/PT2006294E/pt unknown
- 2003-03-27 SI SI200331885T patent/SI2006294T1/sl unknown
- 2003-03-27 CA CA2736921A patent/CA2736921C/en not_active Expired - Fee Related
- 2003-03-27 PT PT03720376T patent/PT1507795E/pt unknown
- 2003-03-27 DK DK08014304.3T patent/DK2006294T3/da active
- 2003-03-27 CA CA2736974A patent/CA2736974C/en not_active Expired - Fee Related
- 2003-03-27 EP EP03720376A patent/EP1507795B1/de not_active Expired - Lifetime
- 2003-03-27 AT AT06015806T patent/ATE416188T1/de active
- 2003-03-27 PL PL373700A patent/PL206306B1/pl unknown
- 2003-03-27 DE DE50310882T patent/DE50310882D1/de not_active Expired - Lifetime
- 2003-03-27 EP EP06015805A patent/EP1734048B1/de not_active Expired - Lifetime
- 2003-03-27 WO PCT/EP2003/003181 patent/WO2003102023A1/de active Application Filing
- 2003-03-27 CA CA2736926A patent/CA2736926C/en not_active Expired - Fee Related
- 2003-03-27 CA CA2736972A patent/CA2736972C/en not_active Expired - Fee Related
- 2003-03-27 PT PT06015805T patent/PT1734048E/pt unknown
- 2003-03-27 ES ES06015806T patent/ES2317379T3/es not_active Expired - Lifetime
- 2003-03-27 PT PT08014305T patent/PT2014673E/pt unknown
- 2003-03-27 SI SI200331451T patent/SI1734048T1/sl unknown
- 2003-03-27 ES ES08014305T patent/ES2348468T3/es not_active Expired - Lifetime
- 2003-03-27 DK DK03720376T patent/DK1507795T3/da active
- 2003-03-27 SI SI200331412T patent/SI1507795T1/sl unknown
- 2003-03-27 DK DK06015806T patent/DK1734049T3/da active
- 2003-03-27 DE DE50313004T patent/DE50313004D1/de not_active Expired - Lifetime
- 2003-03-27 ES ES08014304T patent/ES2350461T3/es not_active Expired - Lifetime
- 2003-03-27 DK DK06015805T patent/DK1734048T3/da active
- 2003-03-27 PL PL390816A patent/PL210356B1/pl unknown
- 2003-03-27 AT AT03720376T patent/ATE410442T1/de active
- 2003-03-27 EP EP08014304A patent/EP2006294B1/de not_active Expired - Lifetime
- 2003-03-27 AT AT08014304T patent/ATE478088T1/de active
- 2003-03-27 DK DK08014305.0T patent/DK2014673T3/da active
- 2003-03-27 PL PL390815A patent/PL211158B1/pl unknown
- 2003-03-27 ES ES03720376T patent/ES2314196T3/es not_active Expired - Lifetime
- 2003-03-27 AT AT08014305T patent/ATE466872T1/de active
- 2003-03-27 DE DE50310613T patent/DE50310613D1/de not_active Expired - Lifetime
- 2003-03-27 EP EP06015806A patent/EP1734049B1/de not_active Expired - Lifetime
- 2003-03-27 ES ES06015805T patent/ES2317378T3/es not_active Expired - Lifetime
- 2003-03-27 PL PL390817A patent/PL211159B1/pl unknown
- 2003-03-27 DE DE50310952T patent/DE50310952D1/de not_active Expired - Lifetime
- 2003-03-27 SI SI200331430T patent/SI1734049T1/sl unknown
- 2003-03-27 CA CA2487137A patent/CA2487137C/en not_active Expired - Fee Related
- 2003-03-27 PT PT06015806T patent/PT1734049E/pt unknown
- 2003-03-27 AT AT06015805T patent/ATE417859T1/de active
- 2003-03-27 EP EP08014305A patent/EP2014673B1/de not_active Expired - Lifetime
- 2003-03-27 PL PL390814A patent/PL211157B1/pl unknown
- 2003-03-27 SI SI200331848T patent/SI2014673T1/sl unknown
- 2003-03-27 AU AU2003224001A patent/AU2003224001B2/en not_active Ceased
- 2003-03-27 DE DE50312701T patent/DE50312701D1/de not_active Expired - Lifetime
-
2004
- 2004-11-23 HR HRP20041108AA patent/HRP20041108B1/hr not_active IP Right Cessation
- 2004-11-29 US US10/999,364 patent/US7396904B2/en not_active Expired - Lifetime
-
2007
- 2007-08-30 US US11/848,062 patent/US7763711B2/en not_active Expired - Lifetime
- 2007-08-30 US US11/848,110 patent/US7666984B2/en not_active Expired - Lifetime
-
2008
- 2008-11-13 CY CY20081101297T patent/CY1108507T1/el unknown
- 2008-12-09 CY CY20081101425T patent/CY1108673T1/el unknown
- 2008-12-30 CY CY20081101508T patent/CY1108680T1/el unknown
-
2009
- 2009-12-15 JP JP2009283583A patent/JP5042300B2/ja not_active Expired - Fee Related
- 2009-12-15 JP JP2009283585A patent/JP5042302B2/ja not_active Expired - Fee Related
- 2009-12-15 JP JP2009283586A patent/JP5042303B2/ja not_active Expired - Fee Related
- 2009-12-15 JP JP2009283584A patent/JP5042301B2/ja not_active Expired - Fee Related
-
2010
- 2010-01-22 US US12/632,463 patent/US8399613B2/en not_active Expired - Lifetime
- 2010-01-22 US US12/632,541 patent/US8536304B2/en not_active Expired - Lifetime
- 2010-02-25 AU AU2010200689A patent/AU2010200689B2/en not_active Ceased
- 2010-07-30 CY CY20101100714T patent/CY1110723T1/el unknown
- 2010-11-03 CY CY20101100991T patent/CY1111174T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111174T1 (el) | Σχετιζομενα με ογκους πεπτιδια δεσμευμενα σε μορια mhc | |
| WO2005116051A3 (de) | An mhc-moleküle bindende tumor-assoziierte peptide | |
| Michels et al. | Acid-mediated prevention of aspartimide formation in solid phase peptide synthesis | |
| CY1118037T1 (el) | Αντισωματα εναντι του αβητα και h χρηση τους | |
| CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
| CY1109786T1 (el) | Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4 | |
| CY1110634T1 (el) | Μεθοδοι προληψης και θεραπειας της νοσου του αλτσχαϊμερ (ad) | |
| CY1106662T1 (el) | Αντι-igf-ir αντισωματα και οι εφαρμογες τους | |
| CY1114643T1 (el) | Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων | |
| UA98295C2 (ru) | Опухолево-ассоциированный пептид, который неспецифически связывается с молекулами ii класса лейкоцитарного антигена человека (hla) | |
| CY1111079T1 (el) | Πεπτιδιο | |
| CY1110530T1 (el) | Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων | |
| CY1111283T1 (el) | Μορια με παρατεταμενες ημι-περιοδους ζωης, συνθεσεις και χρησεις εξ αυτων | |
| HUP0201737A2 (hu) | Anti-CTLA-4 antitestek alkalmazása | |
| CY1109045T1 (el) | Ρετινοειδη για τη θεραπεια του εμφυσηματος | |
| CY1117065T1 (el) | Υβριδικη και διαδοχικη εκφραση νεϊσσεριακα λαμβανομενων πρωτεϊνων | |
| EA200501206A1 (ru) | Производные от сурвивина пептиды и их применение | |
| CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
| CY1107294T1 (el) | Τοπικη συνθεση η οποια περιεχει τουλαχιστον μια βιταμινη d ή ενα αναλογο της βιταμινης d και τουλαχιστον ενα κορτικοστεροειδες | |
| CY1116011T1 (el) | Hla-a*1101-περιορισμενο wt1 πεπτιδιο και φαρμακευτικη συνθεση που το περιλαμβανει | |
| CY1107176T1 (el) | Συνθεσεις και μεθοδος για θεραπεια μολυνσης σε βοοειδη και χοιρους | |
| UA103882C2 (uk) | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина | |
| EA200300381A1 (ru) | Нуклеиновые кислоты и полипептиды нового рецептора | |
| CY1106789T1 (el) | Γενικος φορεας για στοχευση μοριων σε κυτταρα που εκφραζουν gb3 υποδοχεα | |
| CY1106236T1 (el) | Μεθοδοι και συνθεσεις για παραταση ημιπepιοδων αποβολης βιοδραστικων ενωσεων |